Skip to main content

Eagle Pharmaceuticals, Inc.

EGRXDelisted Nov 26, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0000827871

Eagle Pharmaceuticals, Inc. was delisted on Nov 26, 2024; its insiders filed their last Form 4 on Mar 1, 2024; 65 institutions reported holding it in 13F filings for Q3 2024, worth $31.9M in total; no superinvestor held it.

Q2 2021 vs. Q1 2021

How the institutions holding Eagle Pharmaceuticals, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of EGRX: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders155146−9
Shares12.2M12.0M−137.8K (−1.1%)
Value$508.4M$516.0M+$7.60M (+1.5%)

New holders (12)

Institutions that held Eagle Pharmaceuticals, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to EGRX in Q2 2021
InstitutionSharesValue% of portfolio
Tri Locum Partners LP94,922$4.06M1.70%
Krensavage Asset Management, LLC70,804$3.03M1.03%
South Dakota Investment Council55,594$2.38M0.04%
Hein Park Capital Management LP31,977$1.37M0.36%
DuPont Capital Management Corp24,673$1.06M0.02%
Guggenheim Capital LLC16,871$722.0K0.00%
Ziegler Capital Management, LLC16,396$702.0K0.02%
Connors Investor Services Inc6,566$281.0K0.03%
Amalgamated Bank5,997$257.0K0.00%
Squarepoint Ops LLC5,197$222.0K0.00%
Selective Wealth Management, Inc.15$1.00K0.00%
Eubel Brady & Suttman Asset Management Inc2$00.00%

Sold out (21)

Institutions that held Eagle Pharmaceuticals, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.